Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-I&T in mCRPC (Asian Population)
NCT04188587Phase 2Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Jan 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 PSMA I&T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Nanjing First Hospital. Status: unknown.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04188587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188587.